|Positive WB detected in||HeLa cells, HepG2 cells, MCF-7 cells|
|Positive IP detected in||HeLa cells|
|Positive IHC detected in||human breast cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:200-1:800|
|Sample-dependent, check data in validation data gallery|
20366-1-AP targets SUZ12 in WB, IP, IHC,ELISA applications and shows reactivity with human, rat samples.
|Tested Reactivity||human, rat|
|Host / Isotype||Rabbit / IgG|
|Full Name||suppressor of zeste 12 homolog (Drosophila)|
|Calculated molecular weight||83 kDa|
|Observed molecular weight||80-90 kDa|
|GenBank accession number||NM_015355|
|Gene ID (NCBI)||23512|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
SUZ12, also termed CHET9, JJAZ1 or KIAA0160, belongs to the VEFS (VRN2-EMF2-FIS2-SU(Z)12) family. It is a polycomb group (PcG) protein. SUZ12 is a component of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A. A chromosomal aberration involving SUZ12 may be a cause of endometrial stromal tumors.
TRPS1 Suppresses Breast Cancer Epithelial-mesenchymal Transition Program as a Negative Regulator of SUZ12.
Acta Pharmacol Sin
AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
Polycomb repressive complex 2 facilitates the nuclear export of the influenza viral genome through the interaction with M1.
A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.